The gastroretentive drug delivery system is site-specific and allows the drug to remain in the stomach for a prolonged period of time so that it can be released in a controlled manner in the gastrointestinal tract. The purpose of the research work is to formulate and optimize the gastro retensive film (GRF) containing Propranolol hydrochloride in order to prolong the release time and improve the bioavailability. Five basic gastroretensive films were developed by solvent casting method for preliminary trial . The best formulation was subjected for two factor two level design approach. Independent variables selected were concentrations of Eudragit S 100 (X1) and Eudrajit RL 100 (X2) and dependent variables were Folding Endurance (Y1) Tensile strength (Y2) Elongation at break (Y3) and in vitro drug release (Y4). The results of the study indicate optimized formulation (P2) exhibit folding endurance 114, tensile strength 1.3 kg mm2, Elongation at break 22% and in vitro release 46.5 % for 12h. The in vitro release data were well fit into Higuchi and Korsmeyer-Peppas model and followed non-Fickian diffusion mechanism. The gastro retensive formulations can be used in diseases where an extended release of propranolol is required.